SARS-CoV-2 seroprevalence in Spain - Authors' reply.
作者信息
Pollán Marina, Pérez-Gómez Beatriz, Pastor-Barriuso Roberto, Oteo Jesús, Pérez-Olmeda Mayte, Yotti Raquel
机构信息
National Centre for Epidemiology, Institute of Health Carlos III, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health, Institute of Health Carlos III, 28029 Madrid, Spain.
National Centre for Epidemiology, Institute of Health Carlos III, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health, Institute of Health Carlos III, 28029 Madrid, Spain.
出版信息
Lancet. 2020 Nov 7;396(10261):1484-1485. doi: 10.1016/S0140-6736(20)32266-2.
Abstract
摘要
相似文献
1
SARS-CoV-2 seroprevalence in Spain - Authors' reply.
Lancet. 2020 Nov 7;396(10261):1484-1485. doi: 10.1016/S0140-6736(20)32266-2.
2
SARS-CoV-2 seroprevalence in Spain.
Lancet. 2020 Nov 7;396(10261):1484. doi: 10.1016/S0140-6736(20)32272-8.
3
SARS-CoV-2 seroprevalence in Spain.
Lancet. 2020 Nov 7;396(10261):1484. doi: 10.1016/S0140-6736(20)32273-X.
4
Authors' response: COVID-19: how accurate are seroprevalence studies?
Euro Surveill. 2020 Jul;25(30). doi: 10.2807/1560-7917.ES.2020.25.30.2001437.
5
The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France.
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.04.031. Epub 2020 Apr 29.
6
ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.
Lancet. 2020 Nov 7;396(10261):1486-1487. doi: 10.1016/S0140-6736(20)32267-4.
7
CT screening for early diagnosis of SARS-CoV-2 infection - Authors' reply.
Lancet Infect Dis. 2020 Sep;20(9):1011. doi: 10.1016/S1473-3099(20)30247-4. Epub 2020 Mar 26.
8
Prevalence, Characteristics, and Outcome of Asthmatic Patients With Type 2 Diseases in Hospitalized Patients With COVID-19 in Madrid, Spain.
J Investig Allergol Clin Immunol. 2020;30(5):382-384. doi: 10.18176/jiaci.0627. Epub 2020 Jun 18.
9
Seroprevalence and presentation of SARS-CoV-2 in pregnancy.
Lancet. 2020 Aug 22;396(10250):530-531. doi: 10.1016/S0140-6736(20)31714-1. Epub 2020 Aug 6.
10
SARS-CoV-2 seroprevalence in COVID-19 hotspots.
Lancet. 2020 Aug 22;396(10250):514-515. doi: 10.1016/S0140-6736(20)31482-3. Epub 2020 Jul 6.
引用本文的文献
1
Design and Implementation of a Nationwide Population-Based Longitudinal Survey of SARS-CoV-2 Infection in Spain: The ENE-COVID Study.
Am J Public Health. 2023 May;113(5):525-532. doi: 10.2105/AJPH.2022.307167. Epub 2023 Mar 9.
2
SARS-CoV-2 infections in infants in Haiti 2020-2021; evidence from a seroepidemiological cohort.
PLoS One. 2022 Aug 25;17(8):e0273482. doi: 10.1371/journal.pone.0273482. eCollection 2022.
本文引用的文献
1
Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
Clin Chem. 2020 Dec 1;66(12):1538-1547. doi: 10.1093/clinchem/hvaa211.
2
Not just antibodies: B cells and T cells mediate immunity to COVID-19.
Nat Rev Immunol. 2020 Oct;20(10):581-582. doi: 10.1038/s41577-020-00436-4.
3
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Lancet. 2020 Aug 22;396(10250):535-544. doi: 10.1016/S0140-6736(20)31483-5. Epub 2020 Jul 6.
4
Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.
Nat Rev Immunol. 2020 Aug;20(8):457-458. doi: 10.1038/s41577-020-0389-z.
5
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
Nature. 2020 Aug;584(7821):437-442. doi: 10.1038/s41586-020-2456-9. Epub 2020 Jun 18.
6
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
Immunity. 2020 Jun 16;52(6):971-977.e3. doi: 10.1016/j.immuni.2020.04.023. Epub 2020 May 3.
7
Antibody responses to SARS-CoV-2 in patients with COVID-19.
Nat Med. 2020 Jun;26(6):845-848. doi: 10.1038/s41591-020-0897-1. Epub 2020 Apr 29.
8
Use of serological surveys to generate key insights into the changing global landscape of infectious disease.
Lancet. 2016 Aug 13;388(10045):728-30. doi: 10.1016/S0140-6736(16)30164-7. Epub 2016 Apr 5.
Zotero 插件